RxDoctor Payments Data

Justin Allen, MD

Family Medicine · Clinton, ARNPI 1083024848

Payments from drug & device makers

$537in general payments, 2019–2025

Across 33 payments — averaging $16.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Astellas Pharma US Inc$130
  • Abbott$87
  • AstraZeneca$70
  • Amgen$61
  • Johnson & Johnson$40
  • Novo Nordisk$32
  • plus $117 from 6 others

What the payments were for

  • Food & beverage$537100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$537 in reported general payments places this provider in the 45th percentile of 1,347 family medicine providers in Arkansas.

See all family medicine providers in Arkansas

Medicare billing

Part B allowed, 2024
$3,896
Medicare patients
111
Services billed
240

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide138$163,669
JardianceEmpagliflozin77$66,479
EliquisApixaban80$58,734
Trelegy ElliptaFluticasone/Umeclidin/Vilanter48$48,673
LinzessLinaclotide61$43,442
TrulicityDulaglutide28$42,757
XareltoRivaroxaban53$39,450
Tresiba Flextouch U-100Insulin Degludec62$33,154
MounjaroTirzepatide26$29,406
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr33$18,163
FarxigaDapagliflozin Propanediol16$12,706
MyrbetriqMirabegron19$9,333
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog12$6,650
Varenicline Tartrate19$6,122
JanuviaSitagliptin Phosphate17$5,653

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$32$163,669138 claims
Lilly USA, LLCTrulicity, Mounjaro$26$72,16354 claims
Boehringer IngelheimJardiance$11$66,47977 claims
PfizerEliquis$13$58,73480 claims
AbbVieLinzess, Synthroid$17$45,974101 claims
Johnson & JohnsonXarelto$40$39,45053 claims
AstraZenecaFarxiga, Symbicort$70$15,67529 claims
Astellas Pharma US IncMyrbetriq$130$9,33319 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 1,347 family medicine providers in Arkansas.

Other family medicine in Clinton

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →